Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review

World Journal of Gastroenterology

Volumn 12, Issue 48, 2006, Pages 7826-7831

  Chavez Tapia, Norberto Carlos ^a   Barrientos Gutierrez, Tonatiuh ^b   Tellez Ávila, Felix I ^a   Sánchez Ávila, Francisco ^a   Montaño Reyes, Maria Antonieta ^c   Uribe, Misael ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c Instituto de Educación Media Superior de la Ciudad de México   (Mexico)

Author keywords

Diet; Evidence based medicine; Fatty liver; Metformin; Pioglitazone; Rosiglitazone; Steatohepatitis; Systematic review

Indexed keywords

GLITAZONE DERIVATIVE; INSULIN SENSITIZING AGENT; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TROGLITAZONE;

ANEMIA; ARTICLE; CALORIC RESTRICTION; CINAHL; CLINICAL TRIAL; COCHRANE LIBRARY; DIARRHEA; DIET THERAPY; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; EMBASE; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; INFORMATION RETRIEVAL; INSULIN RESISTANCE; LACTATE BLOOD LEVEL; LIVER FAILURE; LIVER FUNCTION TEST; MEDLINE; NONALCOHOLIC FATTY LIVER; SAMPLE SIZE; SIDE EFFECT; SYSTEMATIC REVIEW; UNPLEASANT DREAM; WEIGHT GAIN;

EID: 33846218541     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i48.7826     Document Type: Article

References (26)

1. Ludwig J, Viggiano TF, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438
2. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol 2006; 101: 76-82
3. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-1657
4. Byron D, Minuk GY. Clinical hepatology: profile of an urban, hospital-based practice. Hepatology 1996; 24: 813-815
5. Mendez-Sanchez N, Villa AR, Chavez-Tapia NC, Ponciano-Rodriguez G, Almeda-Valdes P, Gonzalez D, Uribe M. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Ann Hepatol 2005; 4: 52-55
6. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219
7. Mendez-Sanchez N, Chavez-Tapia NC, Uribe M. An update on non-alcoholic fatty liver disease. Rev Invest Clin 2004, 56: 72-82
8. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1702-1704
9. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-894
10. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deved S, Tuzun A, Yesilova Z, Gulsen M, Dagalp K. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004; 19: 537-544
11. Nair S, Diehl AM, Wiseman M, Farr GH Jr, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatiti: a pilot open label trial. Aliment Pharmacol Ther 2004; 20: 23-28
12. Blaszyk H, Ferrentino N, Forsell S, Strader D, Lidofsky S. A Pilot Study of Metformin As Treatment for Nonalcoholic Steatohepatitis: Gastroenterology 2005, 122: M1699
13. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini G. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005; 100: 1082-1090
14. Duseja A, Das A, Das R, Dhiman RK, Chawla Y, Bhansali A, Kaira N. The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the West. Dig Dis Sci 2006; in press
15. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38: 1008-1017
16. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang TJ, Yanovski JA, Kleiner DE, Hoofnagle JH. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39: 188-1896
17. Azuma T, Tomita K, Kato S, Adachi H, Inokuchi S, Kitamura N, Nishimura T, Ishii H. A pilot study of a thiazolidinedione, pioglitazone, in nonalcoholic steatohepatitis: Hepatology 2002; 28: 406A
18. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Clore J, Mills AS. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2: 1107-1115
19. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003; 124: 71-79
20. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, Kral JG. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84: 1513-1517
21. Luyckx FH, Desaive C, Thiry A, Dewe W, Scheen AJ, Gielen JE, Lefebvre PJ. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998; 22: 222-226
22. Amarapurka DN, Amarapurkar AD, Patel ND, Agal S, Baigal R, Gupte P, Pramanik S. Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis. Ann Hepatol 2006; 5: 30-33
23. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112
24. Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Heuman D, Coterrell A, Fisher RA, Contos MJ, Mills AS. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006; 43: 682-689
25. National Institutes of Health, Information on Clinical Trials and Human Research Studies in http://www.clinicaltrials.gov/. Access: 1st april
26. Amarenco P. Polypill strategy vs. prevention clinics for stroke prevention. Cerebrovasc Dis 2006; 21 Suppl 1: 35-40